Skip to main content

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo



Treatment options for patients with recurrent superficial bladder cancer are limited, necessitating aggressive exploration of new treatment strategies that effectively prevent recurrence and progression to invasive disease. We assessed the effects of belinostat (previously PXD101), a novel histone deacetylase inhibitor, on a panel of human bladder cancer cell lines representing superficial and invasive disease, and on a transgenic mouse model of superficial bladder cancer.


Growth inhibition and cell cycle distribution effect of belinostat on 5637, T24, J82, and RT4 urothelial lines were assessed. Ha-ras transgenic mice with established superficial bladder cancer were randomized to receive either belinostat or vehicle alone, and assessed for bladder weight, hematuria, gene expression profiling, and immunohistochemistry (IHC).


Belinostat had a significant linear dose-dependent growth inhibition on all cell lines (IC50 range of 1.0–10.0 μM). The 5637 cell line, which was derived from a superficial papillary tumor, was the most sensitive to treatment. Belinostat (100 mg/kg, intraperitoneal, 5 days each week for 3 weeks) treated mice had less bladder weight (p < 0.05), and no hematuria compared with 6/10 control mice that developed at least one episode. IHC of bladder tumors showed less cell proliferation and a higher expression of p21WAF1 in the belinostat-treated mice. Gene expression profile analysis revealed 56 genes significantly different in the treated group; these included the upregulation of p21WAF1, induction of core histone deacetylase (HDAC), and cell communication genes.


Our data demonstrate that belinostat inhibits bladder cancer and supports the clinical evaluation of belinostat for the treatment of patients with superficial bladder cancer.


Bladder cancer is a major health care problem in the United States and accounts for approximately 13,000 deaths annually [1]. The majority of bladder tumors are initially diagnosed as superficial, however, 70% of patients experience recurrence, and 30% progress to invasive disease [2]. This high rate of recurrence requires patients to undergo lifelong follow-up exams, prophylactic treatments, and additional surgical resection. This protracted natural prevalence of bladder cancer is estimated to affect approximately 500,000 people, and the management of this disease exceeds $4 billion in healthcare expenditures annually [2, 3]. It is critically important to aggressively explore pharmacological treatment strategies that can effectively prevent superficial bladder cancer recurrence and progression to invasive disease.

Histone deacetylase inhibitors (HDACIs) represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (including drug resistant subtypes), induce apoptosis, promote differentiation, inhibit angiogenesis, and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents. Although many HDACIs have been shown to enhance histone acetylation and to increase the expression of tumor suppressor genes in cancerous cells, the exact mechanism(s) that HDACIs effectively inhibit cancer cell growth remains an area of active investigation, and may involve the acetylation of both histone and nonhistone proteins.

HDACIs represent a promising new class of antineoplastic agents for the treatment of bladder cancer. A Phase I clinical trial of suberoylanilide hydroxamic acid (SAHA) showed that 2 out of 4 bladder cancer patients responded to treatment with objective tumor regression and clinical improvement [4]. A new hydroxamate type HDACI known as belinostat was chosen for this study because in vitro experiments showed that it had a potent anti-tumor effect at sub- to low micromolar IC50 potency in several tumor cell lines [58]. Phase I clinical studies have also suggested that belinostat and other HDACIs have anti-tumor effects [912], and that belinostat can specifically inhibit tumor growth in animal models at non-toxic concentrations [5, 6, 8]. We have examined the effects of PXD101 on bladder tumor cell growth and proliferation, both in vitro and in vivo.

Because the majority of bladder cancer is initially diagnosed as superficial and frequently progresses to invasive disease, we chose to use an expanded panel of human transitional cell carcinoma (TCC) cell lines to include superficial variants in addition to the more commonly used highly invasive disease variants.

The lack of a functionally relevant model system for in vivo testing of potential agents has also limited bladder cancer research and therapy development. Currently, anticancer agents are screened in vivo using human xenograft tumor models grown subcutaneously in athymic mice before initiation of a clinical trial. In many cases, xenografts are selected to suit the putative mechanism of the agent tested, the approach being one of proof of principal in an in vivo model, rather than testing the new agent in a clinically relevant and predictive model. Our group has developed a transgenic mouse model of bladder tumorigenesis using a urothelium-specific promoter to drive the urothelial expression of specific activated tumor oncogenes [1315]. One of these models expressed, in a urothelium-specific manner, a constitutively active Ha-ras, known to be a frequent event in about 30–40% of human bladder cancers [16, 17]. Homozygous mice harboring two alleles of the Ha-ras mutant consistently developed low-grade, non-invasive, superficial papillary bladder tumors. These transgenic mice have been characterized in detail and were chosen for our in vivo studies. [1416, 18, 19]. Ha-ras mice reproducibly develop superficial bladder cancer by 3 months of age and continue to form low-grade superficial papillary tumors that rapidly increase in size in the following 3 months. These mice eventually succumb to obstructive neuropathy at 6–7 months. This reproducible and predictable time course of tumor onset and development lent itself as a well-defined model for screening belinostat and other potential chemotherapeutic agents to test their abilities to hinder the development and progression of superficial bladder cancer.

Herein, we show that belinostat treatment inhibited cell growth and proliferation in a dose-dependent fashion and caused cell cycle arrest in our panel of urinary bladder cancer cell lines. We also show that treatment of Ha-ras transgenic bladder cancer mice with belinostat decreased bladder tumor growth with no apparent toxicity and induced p21WAF1 and other HDAC core and cell communication genes. These findings suggest that belinostat may represent a novel adjuvant treatment for patients with superficial recurrent bladder cancer.


Cell culture, proliferation assay and belinostat

The human urinary bladder carcinoma cell lines 5637, T24, J82 and RT4 were obtained from the American Type Culture Collection (Manassas, VA). All tumor cell lines were maintained in DMEM (Sigma; St Louis, MO), supplemented with 10% FBS, and maintained at 37°C with 5% CO2. Cells were seeded into 96-well tissue culture plates (J82 at 2000 cells/well; 5637, T24 and RT4 at 4000 cells/well), allowed to attach and grow for 24 h, exposed to 1–10 μM of belinostat for 48 h, and cell proliferation was assessed using the WST-1 tetrazolium salt cleavage assay kit (Chemicon; Temecula, CA) as per the manufacturer's instructions.

Belinostat has been previously described [6] and was prepared as a 10 mM stock in DMSO/PBS for in vitro studies. For animal studies, belinostat was dissolved in L-Arginine to give a final concentration of 20 mg/ml. This formulation gave sufficient solubility for doses of ≤ 40 mg/kg. Belinostat was kindly provided by CuraGen Corp., TopoTarget and the National Cancer Institute.

Cell cycle analysis

FACS analysis was performed on cells treated with 5 μM belinostat for 48 h, harvested with trypsin-EDTA (Sigma; St Louis, MO), and fixed in absolute ethanol overnight at -20°C. Immediately before analysis, cells were treated with 200 ug/mL DNAse-free RNAseA (Sigma; St Louis, MO) for 30 minutes at 37°C, then treated with 1 mg/mL propidium iodide (Sigma; St Louis, MO). Cells were analyzed using a FACScan (Becton Dickinson; Franklin Lakes, NJ) at an excitation wavelength of 488 nm at the NYU Cancer Institute's Flow Cytometry and Cell Sorting Core Facility.

Generation of UPII-Ha-ras transgenic mice and belinostat treatment

The transgenic model used for this study specifically expressed a constitutively activated Ha-ras oncogene in the urothelium under the control of a 30-kb mouse uroplakin II promoter [15]. Intercrossing of heterozygous mice yielded homozygous offspring that consistently and reproducibly developed superficial bladder cancers at well-defined time points [19, 20]. Homozygous mice were distinguished from heterozygotes by Southern blotting of tail genomic DNA. DNA was digested with Nco I, resolved by gel electrophoresis, and hybridized with a 32P-labeled, UPII probe (600-base pairs), which allowed detection of both the endogenous UPII gene and the mUPII/Ha-ras-M transgene. Densitometric analysis of the genomic Southern blot was used to calculate the relative amount of transgene present by comparing transgene with endogenous UPII gene. Breeding and housing of mice were conducted at the Manhattan VA Medical Center under the guidance of Tung-Tien Sun and Xue-Ru Wu. Animal Studies were carried out at the Manhattan VA Medical Center under IACUC guidelines of the New York Harbor Healthcare System and conformed to their guidelines for the welfare of animals in experimental neoplasia. The starting point of belinostat was set at 3 months of age when all homozygous mice were known to have established bladder tumors. Twenty Ha-ras mice were randomized into two groups of 10 per group. Ten mice received intraperitoneal (IP) injections containing belinostat dissolved in L-Arginine each day for 5 days each week for 3 weeks (100 mg/kg, IP, 5 days each week for 3 weeks), and 10 received IP injections with L-Arginine alone following the same dose scheduling. Mice were weighed twice weekly, checked daily for gross hematuria by applying light pressure on the bladder, and monitored for any changes in behavior or condition. One day after the last dosing (when mice were 3 months and 22 days old) all twenty mice were sacrificed, bladders were removed, weighed after voiding of all urine, necroscopied, divided for RNA isolation, and paraffin embedded for IHC.

Histopathology of mouse bladder tumors

All bladders and tumors were analyzed histopathologically and all were confirmed to be superficial with no evidence of invasion. We also looked for differences in necrosis, mitotic figures, and the extent of tumor burden present in all bladders.

Microarray Analysis

All mouse bladders were processed for total RNA isolation and all subsequent technical procedures including purity and concentration of RNA, cDNA synthesis, biotin labeling of cRNA, and hybridization and scanning of arrays were performed by Genome Explorations, Inc. (Memphis, TN). Briefly, RNA integrity was determined by capillary electrophoresis using the RNA 6000 Nano Lab-on-a-Chip kit and the Bioanalyzer 2100 (Agilent Technologies). In order to obtain sufficient highly pure RNA for gene profiling it was essential to identify and pool the best quality RNA from three animal bladders per treatment group (15 μg). Our transgenic mice represented a homogeneous biologic entity. Similarly, other investigators using the same GeneChips have pooled RNA from transgenic mice organs for subsequent microarray analysis [21, 22]. Preparation of the cRNA and the subsequent microarray processes were performed as described in the Affymetrix GeneChip expression analysis technical manual (Affymetrix; Santa Clara, CA). Briefly, cRNA was hybridized to Affymetrix MOE 430 2.0 short oligomer arrays, which detect approximately 45,000 mouse transcripts representing over 34,000 well-characterized mouse genes. The results were analyzed using programs resident in GeneChip Operating System v1.4 (GCOS; Affymetrix). Conversion of gene names or accession numbers to Affymetrix probe set IDs was accomplished using NetAffx. Probe sets were identified by pair-wise comparison in GCOS using a 2-fold change threshold, and the GCOS-generated Change calls and Detection calls were used in our filtering criteria to identify robust expression changes. Signal intensity heat map figures were generated using Due to an inadequate amount of bladder tissue, gene analysis was performed on pooled RNA samples with no replicates. Our gene analysis was an investigational type of array given that a traditional p-value could not be generated due to the lack of sufficient individual RNA samples.

Immunohistochemistry of mouse bladder tumors

Freshly dissected bladder tissues were fixed in 10% buffered formalin and processed routinely for paraffin embedding. Three-micron tissue sections were stained with hemotoxylin/eosin and examined microscopically. To determine the proliferative and apoptotic capacity of the tumors, we stained sections for the expression of proliferation specific antigen (Ki-67) using the mouse monoclonal antibody MIB1 (Immunotech SA; France), and assessed the expression of p21WAF1 using MAb clone 2G12 (PharMingen; San Diego, CA), both as described previously [23].

Image quantitation of Ki67 and p21WAF1 IHC staining

The quantitative digital analysis of the IHC stained slides for Ki67 and p21WAF1 involved the following modifications from methodology previously developed [24, 25] using Kodak Molecular Imaging (MI) software (Ver 4.0, New Haven, CT): all slides were reviewed by a pathologist who captured a representative area using Olympus Digital Vision v3.0 (Center Valley, PA) at 20× objective magnification and output as a TIFF file. The image was imported into Adobe Photoshop CS2 (Adobe Systems Inc.; San Jose CA) and the image color was standardized across all images using the auto level function. In Photoshop, the wand function was then used to subtract immunonegative portions of the image. Tumor images excluded areas containing preparation artifact and any necrotic or benign regions. The final image was imported into Kodak MI where automatic conversion to grayscale occurred followed by utilization of the "automatic region-of-interest" function for the entire image. The density slice mode was used with the threshold visually adjusted (over the setting of 0–255) to select for only immunopositive staining tumor pixels. The pixel size was unrestricted, and the automatic find function was set to search for immunopositive pixels using smooth edges. The interior area of the positively staining pixel regions-of-interest was determined by the Kodak MI analysis, and the sum was calculated using Microsoft Excel. To obtain percent staining, the sum of the interior area of the positively staining pixels was divided by the entire interior pixel area for the image being analyzed. To obtain fold change in staining for p21WAF1 in the belinostat-treated mice over the arginine-treated group, the percent staining of the belinostat group was divided by the percent staining of the arginine treatment group. To obtain fold change in staining for Ki67 in the arginine treated mice over the belinostat-treated group, the percent staining of the arginine group was divided by the percent staining of the belinostat treated group.

Statistical Analysis

Cell proliferation and FACS analysis experiments were performed at least three times independently, with 3–8 repeats at each data point. Statistical analysis was performed using GraphPad Instat version 3.0 (Graph Pad Software Inc.; San Diego, CA). Statistical significance was calculated using the Students two-tailed t test, where p < 0.05 was considered significant.


Belinostat inhibited bladder cancer cell growth

The in vitro treatment of all four urothelial carcinoma cell lines at 1–5 μM belinostat for 48 h caused a dose-dependent inhibition of proliferation, with the most potent inhibitory effect occurring on 5637 cells (IC50 of 1.0 μM), and the least effect occurring on RT4 cells (IC50 of 10.0 μM). T24 and J82 cell lines had an IC50 of 3.5 and 6.0 μM, respectively. Treatment with 5 μM belinostat for 48 h caused a 71% (± 0.2, SEM) decrease in cell growth and proliferation for 5637 cells, 51% (± 1.0) for T24, 41% (± 2.0) for J82, and 23% (± 7.9) for RT4 cells (Figure 1). All cell lines, except the RT4 line, showed a significant growth inhibition (GI) when compared to control at all concentrations of belinostat (1, 2 and 5 μM) (p < 0.001). RT4 cells only showed a significant GI at 5 μM belinostat when compared to control (p = 0.01).

Figure 1

Inhibition of bladder cancer cell proliferation by belinostat at 1, 2 and 5 μM for 48 h in the human urinary bladder cancer cell lines 5637, T24, J82 and RT4. Percent inhibition from control was determined using the WST-1 tetrazolium salt cleavage assay. Bars are representative of at least 3 independent experiments and are the mean of at least 8 wells per condition. Error bars indicate SEM.

Induction of cell cycle arrest by belinostat

Cell cycle analysis showed that, 48 h after the 5637 bladder carcinoma cells were treated with 5 μM belinostat, there was an 18% (± 1.0, SD) increase of cells in the G0-G1 phase, and a 16% (± 1.0) decrease in S phase (Figure 2); indicating the cells were arrested at the G0-G1transition. The J82 cells showed a moderate 10% (± 0.7) decrease in S phase cells. RT4 cells showed minor changes in cell cycle parameters: 6% (± 0.8) build up of cells in G0-G1, and 5% (± 0.4) decrease in S phase.

Figure 2

Effect of belinostat on cell cycle distribution in 5637 cells. 5637 cells were the most sensitive to belinostat treatment and showed the greatest accumulation of G0-G1 cells, decrease in S phase cells and increase in G2-M phase cells after treatment. Cells cultured with 5 μM belinostat for 48 h were analyzed by flow cytometry, and percent cell cycle distribution was assessed by standard histogram analysis.

Belinostat reduced mice bladder weights, decreased hematuria and was well-tolerated

The transgenic mice used in this study all had established superficial bladder cancer when treatment was initiated, therefore this study was one that explored the effect of belinostat on established superficial bladder cancer, and not one that sought to prevent initiation. The bladder epithelium of our Ras-expressing transgenic mice undergo tumorigenic changes resulting in a 300% increase in bladder weight at 3 months of age (30 mg Ha-ras bladder versus 10 mg normal non-transgenic mouse bladder). Consistent with previous studies in non-transgenic mice [26], the increase in male bladder weight due to tumor formation occurred at a faster rate than in females. Belinostat caused a 50% (p = 0.03; Figure 3a) and 36% (p = 0.04; Figure 3b) decrease in the weights of Ras-expressing bladders of the male and female transgenic mice, respectively. While untreated Ras-expressing transgenic mice showed many episodes of hematuria (male mice 2/4: one mouse with one episode on day 3, and one mouse with one episode on day 7 and day 16; female mice 4/6: two mice with one episode on day 7, and two mice with one episode on day 16), none of the belinostat-treated mice had hematuria (male mice 0/4, female mice 0/5). The lack of any incidence of hematuria demonstrated that all mice being treated with belinostat experienced decreased progression of bladder disease compared to vehicle alone. Haematuria in this model might be considered a sign of bladder cancer. Although development of haematuria is not in complete parallel with the development of bladder cancer, haematuria has been consistently reported as the most common symptom of bladder cancer in humans [27]. The comparison of the rate of haematuria in the control arm versus that in the belinostat treated arm was consistent with our suggestion that haematuria in our mouse model mirrors, at least in part, the human counterpart. In addition, belinostat showed no detectable toxicity as evaluated by weight (male and female belinostat-treated mice showed a 1% (p = 0.19) and 11% (p = 0.70) increase in body weight, respectively. Pathological examination at necroscopy also showed no significant abnormalities (including necrosis or mitotic figures) between the two groups. Bladder tumors in the treated mice were smaller and occupied less space of the total bladder capacity. There were no striking histopathological differences between the two treatment groups, however IHC of Ki67 showed an increase in cell proliferation in the control mice over that of belinostat-treated mice (Figure 4a). IHC analysis also showed an increase of p21WAF1 expression in the belinostat-treated mice over that of the control (Figure 4b).

Figure 3

Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice. Ha-ras transgenic mice with established superficial bladder cancer were randomized to receive either belinostat dissolved in L-Arginine (100 mg/kg, IP, qd, 5 days on, 2 days off, 3 cycles) or L-Arginine alone as a control following the same dose scheduling. All bladders were voided of urine prior to weighing. Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-ras transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. A, Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). B, Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).

Figure 4

IHC staining of transgenic mice bladders for A, the cell proliferation marker Ki67 and B, P21 in L-Arginine treated (left panel) and belinostat-treated bladder cancer mice (right panel). Images are representative of 9 belinostat-treated mice and 10 control treated with vehicle alone (L-Arginine) selected by a pathologist. All images at 20× objective magnification.

Belinostat induced p21WAF1, HDAC core and cell communication genes

cDNA microarray studies of mouse bladder tumors revealed 22 HDAC core genes that were significantly up- or downregulated due to belinostat treatment (Table 1). These genes are involved in cell cycle regulation, apoptosis and DNA synthesis. The most prominently upregulated genes due to belinostat treatment were metallothionein 1, hepatoma derived growth factor, CTP synthase, fucosidase, and p21WAF1. The most dominantly downregulated genes were clusterin, histone H2be, and tubulin alpha 4. We also determined that 34 cell communication genes were differentially expressed due to belinostat treatment (Table 2).

Table 1 Belinostat induces P21WAF1 and other HDAC core genes in transgenic mice bladders. Summary of changes in transgenic mice bladder gene expression for belinostat-treated versus control
Table 2 Belinostat induces 34 genes involved in cellular communication. Summary of fold changes in transgenic mice bladder gene expression for belinostat-treated versus control


This is the first study to demonstrate the low micromolar potency of belinostat in human bladder cancer cells. Although we did not conduct a comparative study and test any other HDACIs alongside belinostat, we feel that a non-direct comparison to other HDACs is important. Our data demonstrated that in comparison with other HDACIs such as valproic acid and sodium butyrate, belinostat had greater potency, required only 3.5 μM to achieve an IC50 in T24 cells, and also had a relatively lower micromolar IC50 range of 1.0–10.0 μM for the 5637, J82 and RT4 cell lines (IC50 data for J82 and RT4 not shown). Other HDACIs, such as valproic acid, have required millimolar concentrations in order to achieve an IC50 in the T24 cell line [2830]. This high concentration of valproic acid resulted in the dose-limiting neurotoxicity observed in the clinical setting [28]. Other groups have had better success using 10–20 μM SAHA to achieve an IC50 on T24 cells [31]. Belinostat had a similar effect on cell cycle distribution compared with other HDACIs such as trichostatin A (TSA), sodium butyrate, and SAHA [29, 32, 33]. All of these agents have been reported to decrease S-phase and G2-M phase cells, and increase the accumulation of G0-G1 phase cells after treatment.

Our study revealed that the 5637 cells were the most sensitive to the effect of belinostat on cell cycle distribution and proliferation. The preferential response of this cell line might be explained by its genetic profile, as well as the mechanism of action that belinostat exerted on it. 5637 cells are p53 mutant, have a p16 deletion, and express p73 in IHC staining [34]. In the future, screening a patient's tumor for these markers may give an indication of potential favorable clinical response to belinostat.

For assessment of apoptosis, both in vitro assays on all four cell lines and in vivo caspase 3 IHC staining of mice bladders did not show any significant difference between the treated and un-treated groups (data not shown). Therefore, we believe that cell cycle arrest via p21 up-regulation, not apoptosis, is the predominant mechanism of tumor inhibition in our current system.

Gene expression analysis of belinostat-treated mice showed increased p21WAF1 gene transcript expression. This finding was validated by IHC analysis, where p21WAF1 expression in belinostat-treated mice was also upregulated in comparison with control mice. IHC image analysis of Ki67 showed a 17.8 fold increase of cell proliferation in the control mice over that of belinostat-treated mice. IHC image analysis of p21WAF1 expression showed an 11.7 fold increase in the belinostat-treated mice. Expression of the cell cycle kinase inhibitor p21 is one of the most commonly induced genes by HDACIs such as TSA, SAHA, and sodium butyrate [31, 33, 3537]. Recent studies have shown that belinostat induces p21WAF1 in ovarian, colon, lung, breast, prostate and melanoma cell lines [6]. p21WAF1 is a cyclin-dependent kinase inhibitor that is associated with activities that lead to cell cycle arrest, and apoptosis. Belinostat also upregulated metallothionine 1, another member of the HDAC core gene family, by 4.3 fold. Metallothioneins are a group of cysteine-rich stress response proteins that scavenge reactive oxygen species and heavy metals. Upregulation of metallothionine 1L has also been reported by treatment of T24 cells by three other HDACIs: SAHA, TSA, and MS-27–275 [38], and treatment of mouse lymphosarcoma cells by TSA and depsipeptide [39]. Tubulin alpha 4 was downregulated in belinostat-treated mice and confirmed previously reported data that tubulin is a target of belinostat [8]. Alteration of microtubulin function is commonly exerted by a wide variety of chemotherapeutic agents such as the vinca alkaloids and taxanes, two families of agents that effectively inhibit cell division, proliferation and function. Disruption of tubulin function has been implicated as a critical downstream event for initiating apoptosis in cancer cells [40].

Conversely, our expression profile results showed that some genes such as histone 2, and those known to regulate DNA synthesis (CTP synthase) and apoptosis (clusterin), were oppositely regulated by belinostat compared to other reports that used different HDACIs on bladder and breast carcinoma cells [38]. One possible explanation for this effect by belinostat could be due to the very nature of HDAC inhibition. HDAC inhibition is known to disrupt cell cycle function due to its alteration of chromatin function in carcinoma cells. This undoubtedly causes alterations in normal nuclear processes involved in cell cycle, apoptosis, and proliferation, and subsequently alters normal gene expression patterns. Belinostat could affect these genes differently than other HDACIs while still being able to induce cell cycle arrest, cell growth inhibition, and p21 expression, as we have demonstrated in our data. Our results illustrate the complexity surrounding the regulation of gene transcription that occurs through chromatin remodeling by all HDACIs, including belinostat. Most importantly, gene expression profiling in our transgenic model showed that belinostat induced a common set of core HDAC genes similar to those previously reported in the T24 human bladder cancer cell line treated with different HDACIs [38].

Gene expression analysis also showed that 34 genes involved in cell communication were significantly up or down regulated due to belinostat treatment. HDACIs are known to alter the expression of genes involved in cellular communication and signal transduction [41]. One of the most predominantly upregulated genes was secreted frizzled-related sequence protein 1 (SFRP1). Dysregulation of the SFRP family in human cancers has been correlated with the HDAC inhibitor Trichostatin A [42]. This gene has also been shown to induce apoptosis in MCF7 breast cancer cells [43]. We also found that belinostat induced the dysregulation of Adiponectin (Adipoq). The altered expression of this gene has also been shown to occur with the HDAC inhibitor valproic acid [44].

While the data in this report establish the link between dose-response relationships in both in vitro and in vivo efficacy models, it is important to note that both the in vivo dosing schedule and in vitro concentration ranges chosen for these experiments are achievable in patients. In the current clinical setting, belinostat is dosed at the MTD (1000 mg/m2) given intravenously, which results in a Cmax of ~100 μM and AUC0-tof ~31 μM*hr/mL (unpublished data), treatments are given 5 times per week in a 3 week cycle. Exposure of cells in culture to belinostat concentrations of 1–5 μM over 48 hr in this study is well within the clinical range and this resulted in significant cell growth inhibition and cell cycle arrest. In accordance with the clinical trial, in this study, belinostat, administered in transgenic mice five times per week, showed efficacy at a dose in the lower range of clinical dosing, 100 mg/kg, human equivalent dose of 300 mg/m2. Hence, both in vitro and in vivo dosing of belinostat used in this study are within clinically achievable dosing regimens.

Our Ha-ras transgenic model of human bladder cancer offered a unique correlation to the onset and progression of human superficial bladder cancer not available in the xenograft system. In these mice, superficial tumors occupied the entire bladder volume at the endpoint of this study making miscrodissection impractical. Since microdissection could not be performed we weighed the entire bladder from each animal and used it as a surrogate marker to assess tumor burden. However, when all mice were sacrificed and underwent pathological dissection and analysis, all bladder tumors in the belinostat-treated mice were smaller and occupied less space of the total bladder capacity than untreated mice. Belinostat-treated mice had a lower incidence of bladder tumors compared to untreated mice based on total bladder weight. This indicates that belinostat was able to decrease the progression of existing established superficial bladder cancer. Of note, the Ha-ras mice used in this study all have low-grade superficial bladder tumors starting at 3 months that progress to occupy the entire bladder and force the mice to succumb to obstructive neuropathy at 6–7 months of age. Although the mice in this study were not allowed to succumb to obstructive neuropathy, we anticipate that untreated mice would succumb to obstructive neuropathy quicker than those mice treated with belinostat based on the former's increased endpoint tumor burden. Another alternative to microdissection would be the use of the novel computed tomography system developed to image the urinary tract and tumors in live mice [45]. This technique may offer potential to quantitatively assess tumor size in superficial transgenic mice in future experiments.

Previous phase I trials of the histone deacetylase inhibitors phenylbutyrate [9] and depsipeptide [10] have shown minimal toxicity to patients. A recent phase 1 trial of MS-275, a benzamide derivative with potent HDAC inhibition and antitumor activity in preclinical models, was used in patients with advanced myeloid leukemias and showed no response by classical criteria, but suggested a potentially better clinical outcome if tested in a cohort of patients with less-advanced disease [46]. A phase 2 trial using vorinostat in combination with carboplatin and paclitaxel showed that both dose schedules used were well tolerated, and the study had encouraging anticancer activity in patients with previously untreated non-small cell lung cancer [47].

When used in combination with established chemotherapeutics such as carboplatin and docetaxel, belinostat was found to synergistically inhibit both in vitro and in vivo ovarian cancer cell growth [8]. Belinostat has also been shown to synergize with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo, and demonstrated a strong rationale for the use of belinostat and 5-fluorouracil in combination in the clinic [5]. Currently, belinostat is undergoing investigation for a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade (bortezomib) for Injection. Promising results include good tolerance and a broad range of antitumor activity. Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, colorectal, ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. Given the well tolerability of belinostat, these results indicate that further investigation of belinostat as a bladder cancer treatment, either used alone or in combination with other chemotherapeutics, is well warranted.


In this study, we showed that belinostat induced growth inhibition and cell cycle arrest in a panel of human TCC urinary bladder cells in vitro at low micromolar concentrations. Belinostat increased gene and IHC expression of p21WAF1 at both mRNA and protein levels, and treatment with belinostat decreased cell growth and proliferation in our transgenic mouse model of superficial bladder cancer at a concentration that was without apparent toxicity to the mice. Taken together, these findings suggest that belinostat is a potent and relatively tolerable agent for the treatment of superficial urinary bladder cancer.


  1. 1.

    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54: 8-29.

    Article  PubMed  Google Scholar 

  2. 2.

    Society AC. What are the key statistics for bladder cancer?. Accessed January 2007, []

  3. 3.

    Earel JK, VanOosten RL, Griffith TS: Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006, 66: 499-507. 10.1158/0008-5472.CAN-05-3017.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003, 9: 3578-88.

    CAS  PubMed  Google Scholar 

  5. 5.

    Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW: The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2007, 60: 275-83. 10.1007/s00280-006-0374-7.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003, 2 (8): 721-728.

    CAS  PubMed  Google Scholar 

  7. 7.

    Beck HC, Nielsen EC, Matthiesen R, Jensen LH, Sehested M, Finn P, Grauslund M, Hansen AM, Jensen ON: Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics. 2006, 5 (7): 1314-1325. 10.1074/mcp.M600007-MCP200.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M: Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006, 5: 2086-2095. 10.1158/1535-7163.MCT-06-0111.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC: Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120 hr infusion schedule. Clin Cancer Res. 2001, 7: 3047-55.

    CAS  PubMed  Google Scholar 

  10. 10.

    Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002, 8 (3): 718-728.

    CAS  PubMed  Google Scholar 

  11. 11.

    Hansen M, Gimsing P, Rasmussen A, Jensen PB, Knudsen LM: A Phase I Study of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Patients with Advanced Hematological Tumors (abstract). J Clin Oncology. ASCO Annual Meeting Proceedings. 2005, 16S: 3137-

    Google Scholar 

  12. 12.

    Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1: 194-202. 10.1038/35106079.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Wu XR, Medina JJ, Sun TT: Selective interactions of UPIa and UPIb, two members of the transmembrane 4 superfamily, with distinct single transmembrane-domained proteins in differentiated urothelial cells. J Biol Chem. 1995, 270: 29752-9. 10.1074/jbc.270.50.29752.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR: Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999, 59: 3512-7.

    CAS  PubMed  Google Scholar 

  15. 15.

    Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, Wu XR: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001, 20: 1973-80. 10.1038/sj.onc.1204315.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, Koss LG: Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992, 23 (11): 1199-1204. 10.1016/0046-8177(92)90285-B.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, Summerhayes IC: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst. 1995, 87 (2): 129-133. 10.1093/jnci/87.2.129.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Shapiro E, Huang HY, Wu XR: Uroplakin and androgen receptor expression in the human fetal genital tract: insights into the development of the vagina. J Urol. 2000, 164: 1048-51. 10.1016/S0022-5347(05)67247-3.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, Sun TT, Wu XR: Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest. 2007, 117: 314-325. 10.1172/JCI30062.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  20. 20.

    Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005, 5: 713-25. 10.1038/nrc1697.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Nair S, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Liew C, Chan JY, Kong AN: Toxicogenomics of endoplasmic reticulum stress inducer tunicamycin in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Toxicol Lett. 2007, 168: 21-39. 10.1016/j.toxlet.2006.10.012.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  22. 22.

    Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, Lin W, Reddy B, Chan JY, Kong AN: Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci. 2006, 79: 1944-55. 10.1016/j.lfs.2006.06.019.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI: Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999, 91: 1869-76. 10.1093/jnci/91.21.1869.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Roth JM, Akalu A, Zelmanovich A, Policarpio D, Ng B, MacDonald S, Formenti S, Liebes L, Brooks PC: Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol. 2005, 166: 901-11.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  25. 25.

    Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM: Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol. 2005, 23: 6107-16. 10.1200/JCO.2005.01.136.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, Kiemeney LA: Gender differences in stage-adjusted bladder cancer survival. Urology. 2000, 55: 876-80. 10.1016/S0090-4295(00)00523-9.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Grossfeld GD, Carroll PR: Evaluation of asymptomatic microscopic haematuria. Urol Clin North Am. 1998, 25: 661-76. 10.1016/S0094-0143(05)70055-0.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Höti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R: Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther. 2006, 14: 768-78. 10.1016/j.ymthe.2006.07.009.

    Article  PubMed  Google Scholar 

  29. 29.

    Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP: Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in vitro. Clin Cancer Res. 2003, 9: 5749-55.

    CAS  PubMed  Google Scholar 

  30. 30.

    Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R: Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther. 2006, 319: 533-42. 10.1124/jpet.106.106658.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci. 2000, 97: 10014-9. 10.1073/pnas.180316197.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  32. 32.

    Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, Tamura Y, Satone A, Ide W, Hashimoto I, Kamada H: Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 2001, 18: 109-14. 10.1007/BF02479423.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ: Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol. 2006, 13: 581-6. 10.1111/j.1442-2042.2006.01344.x.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C: Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002, 62: 6973-80.

    CAS  PubMed  Google Scholar 

  35. 35.

    Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T: Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci. 1999, 886: 195-9. 10.1111/j.1749-6632.1999.tb09415.x.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Gui CY, Ngo L, Xu WS, Richon VM, Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 2004, 101: 1241-6. 10.1073/pnas.0307708100.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  37. 37.

    Chopin V, Toillon RA, Jouy N, Le Bourhis X: P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004, 23: 21-9. 10.1038/sj.onc.1207020.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003, 2: 151-63.

    CAS  PubMed  Google Scholar 

  39. 39.

    Ghoshal K, Datta J, Majumder S, Bai S, Dong X, Parthun M, Jacob ST: Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol. 2002, 22: 8302-19. 10.1128/MCB.22.23.8302-8319.2002.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  40. 40.

    Pellegrini F, Budman DR: Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005, 23: 264-73. 10.1081/CNV-200055970.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Chiba T, Yokosuka O, Fukai K, Kojima H, Tada M, Arai M, Imazeki F, Saisho H: Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology. 2004, 66: 481-491. 10.1159/000079503.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Qi J, Zhu YQ, Luo J, Tao WH: Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 2006, 12: 7113-7.

    PubMed Central  CAS  PubMed  Google Scholar 

  43. 43.

    Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, Tomei LD, Umansky SR: SARPS: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci USA. 1997, 94: 13636-41. 10.1073/pnas.94.25.13636.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  44. 44.

    Qiao L, Schaack J, Shao J: Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology. 2006, 147: 865-74. 10.1210/en.2005-1030.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Johnson AM, Conover DL, Huang J, Messing EM, Ning R, O'Connell MJ, Rossi MA, Sun TT, Wood RW, Wu XR, Reeder JE: Early detection and measurement of urothelial tumors in mice. Urology. 2006, 67: 1309-14. 10.1016/j.urology.2005.12.011.

    Article  PubMed  Google Scholar 

  46. 46.

    Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE: Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007, 109: 2781-90.

    PubMed Central  CAS  PubMed  Google Scholar 

  47. 47.

    Ramalingam SS, Parise RA, Ramananthan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP: Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies. Clin Cancer Res. 2007, 13: 3605-10. 10.1158/1078-0432.CCR-07-0162.

    CAS  Article  PubMed  Google Scholar 

Download references


The authors would like to thank Dr. Thomas Hawthorne for his input in the clinical PK data analysis, and for the technical assistance of Hong Zhong and Jessie Z. Yu.

Sources of Grant Support: MB and LL were supported by The Chemotherapy Foundation, IO was supported by an NYU Cancer Institute Grant, and XW was supported by VA Research Service (Merit Review), NIH DK52206, and NIH DK69688 grants.

Author information



Corresponding author

Correspondence to Iman Osman.

Additional information

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

All authors have read and approved the final manuscript. MB carried out the proliferation and FACs analysis studies, participated in interpretation of the data, data analysis, and manuscript writing. JY carried out the transgenic mice data collection and coordinated the gene expression analysis. HY analyzed the histology and immunohistochemistry. LC performed IHC staining and participated in manuscript drafting. LL participated in data analysis and drafting of the manuscript. GA and XQ participated in study design and drafting of the manuscript. DB participated in study design and the drafting of the manuscript. TS and XW participated in study design, interpretation of the data and manuscript writing. IO designed the study, and led the data interpretation and manuscript writing.

Authors’ original submitted files for images

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Buckley, M.T., Yoon, J., Yee, H. et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 5, 49 (2007).

Download citation


  • Bladder Cancer
  • Bladder Tumor
  • SAHA
  • Superficial Bladder Cancer
  • Hepatoma Derive Growth Factor